Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
This study is enrolling participants by invitation only.
Study NCT00992693   Information provided by U.S. Army Medical Research and Materiel Command

First Received on October 8, 2009.   Last Updated on May 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Crimean-Congo Hemorrhagic Fever
Lassa Fever
Additional conditions recognized in this trial
Fever
Hemorrhagic Fever, Crimean
Hemorrhagic Fevers, Viral
More general conditions related to this trial
Arbovirus Infections
Arenaviridae Infections
Body Temperature Changes
Bunyaviridae Infections
RNA Virus Infections
Signs and Symptoms
Tick-Borne Diseases
Virus Diseases
Interventions listed in this trial
Ribavirin (Virazole) Injection
Additional drug interventions recognized in this trial
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
U.S. Army Medical Research and Materiel Command
Valeant Pharmaceuticals International, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services